Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38936378

Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2024 Jul
First author
Gupta AA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2024 Jul;25(7):828-830. doi: 10.1016/S1470-2045(24)00287-0.
    note
    Source null
    related pmid
    38936374
    relationship
    Comment in
  2. citation
    Transl Pediatr. 2025 Apr 30;14(4):769-772. doi: 10.21037/tp-2024-605.
    note
    Source null
    related pmid
    40386363
    relationship
    Comment in

Authors and identifiers

  1. name
    Gupta AA
    type
    Author
  2. name
    Xue W
    type
    Author
  3. name
    Harrison DJ
    type
    Author
  4. name
    Hawkins DS
    type
    Author
  5. name
    Dasgupta R
    type
    Author
  6. name
    Wolden S
    type
    Author
  7. name
    Shulkin B
    type
    Author
  8. name
    Qumseya A
    type
    Author
  9. name
    Routh JC
    type
    Author
  10. name
    MacDonald T
    type
    Author
  11. name
    Feinberg S
    type
    Author
  12. name
    Crompton B
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gupta AA
    type
    Author
  2. name
    Xue W
    type
    Author
  3. name
    Harrison DJ
    type
    Author
  4. name
    Hawkins DS
    type
    Author
  5. name
    Dasgupta R
    type
    Author
  6. name
    Wolden S
    type
    Author
  7. name
    Shulkin B
    type
    Author
  8. name
    Qumseya A
    type
    Author
  9. name
    Routh JC
    type
    Author
  10. name
    MacDonald T
    type
    Author
  11. name
    Feinberg S
    type
    Author
  12. name
    Crompton B
    type
    Author
bibliography ids
  1. nci-bib-325122b5aa5eecb2bd9f3790
book metadata
content sha256
ff2482e524f5820110c2db5c65c013e1c3698ce43adff059efaf13fba6289188
document type
citation
dois
  1. 10.1016/S1470-2045(24)00255-9
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:38936378
immutable id
pubmed:38936378@ff2482e524f5820110c2db5c65c013e1c3698ce43adff059efaf13fba6289188
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
912-921
volume
25
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2024 Jul;25(7):828-830. doi: 10.1016/S1470-2045(24)00287-0.
    note
    Source null
    related pmid
    38936374
    relationship
    Comment in
  2. citation
    Transl Pediatr. 2025 Apr 30;14(4):769-772. doi: 10.21037/tp-2024-605.
    note
    Source null
    related pmid
    40386363
    relationship
    Comment in
outcomes validated
false
pmid
38936378
provenance
batch id
3e43afde6f26fc8df6da
provider
NCBI PubMed ESummary
record sha256
b4d335417a6c4059da180885c620a31f7882d376f23d04074a1afb607677a1d8
response sha256
fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
retrieved at
2026-09-09T23:48:21.145285+00:00
publication date
display
2024 Jul
precision
month
year
2024
publication types
  1. Journal Article
  2. Clinical Trial, Phase III
  3. Randomized Controlled Trial
  4. Multicenter Study
  5. Research Support, N.I.H., Extramural
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/38936378/
title
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.

Preserved source evidence · Not medical advice